Wednesday, October 14, 2026
Via News Knowledge File

Snowflake Inc.

organization80% conf.·synced Aug 13, 2026

Cloud-based data warehousing company

52
sourced metrics
302
relationships
20
stated objectives
8
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Customers Over 1m Yoy Growth
27percent
Customers Over 10m Yoy Growth
56percent
Customers Over 10m Annual Spend
56customers
Customer Growth
40percent
Backlog
9.21USD
Analyst Target Price
239USD
Customers Over 1m Annual Spend
733customers
Net New Customers
740customers
Implied Upside
55percent
Gross Margin Target
75percent
Gaap Operating Loss
-318.2USD
Forward Pe Ratio
84.3ratio
Fcf Headwind From Observe
150basis_points
Fair Value Narrative
78.83USD
Fair Value Dcf
236.22USD
Enterprise Value
50USD
Earnings Growth Forecast
33.9percent
Stock Price
244.82USD
Jun 2, 2026source

Stated objectives

FY2025 revenue guidance

source
target: 4.44B USD by 2025-01-01 00:00:00stated

Q4 product revenue guidance of $1.19B-$1.2B

source
target: 1.195 billion USD stated

FY revenue guidance of $4.44B

source
target: 4.44 billion USD stated

Q4 product revenue guidance

source
target: $1.19B-$1.2B stated

FY revenue guidance

source
target: $4.44B stated

Achieve full-year revenue of $4.44 billion

source
target: 4.44 billion by 2025-01-01 00:00:00stated

Q4 product revenue target

source
target: $1.19B to $1.2B stated

Full-year revenue target

source
target: $4.44B by 2025-01-01 00:00:00stated

Q4 product revenue guidance

source
target: 1.19-1.2 billion USD stated

Full-year revenue guidance

source
target: 4.44 billion USD stated

Relationship graph · 302 connections

Developed by
68
Customer of
46
Employs
28
Competes with
28
Covered by
22
Built on
16
Partners with
12
headquartered in
8

Via News coverage

This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com